<DOC>
	<DOCNO>NCT00820742</DOCNO>
	<brief_summary>An open label , non-comparative , multicenter , non-interventional , post marketing surveillance study evaluate overall safety tolerability pegaptanib sodium ( Macugen ) treatment Filipino patient neovascular age-related macular degeneration base incidence adverse event evaluate efficacy base visual acuity , patient 's physician 's overall satisfaction tolerability efficacy .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Pegaptanib Sodium ( Macugen ) Filipino Patients With Neovascular Age Related Macular Degeneration .</brief_title>
	<detailed_description>Open-label , non-comparative , non-interventional study</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Must least one eye diagnose neovascular degeneration Presence cause choroidal neovascularization , include pathologic myopia ( spherical equivalent 8 diopter negative , axial length 25mm ) , ocular histoplasmosis syndrome , angioid streak , choroidal rupture , multifocal choroiditis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>A5751025</keyword>
</DOC>